Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, recipient of a RMAT designation in the U.S.A. and for which we are in preparation to commence a Phase 3 clinical trial in no option refractory disabling angina.

INVESTMENT HIGHLIGHTS

**Late-stage therapeutics development company**
- Pioneering advancements of cell therapies in cardiovascular disease
- Three principal development programs; 2 designated “breakthrough”*
  - CD34+ cells for ischemic repair (CLBS12*, CLBS14*, CLBS16)

**CD34+ cell therapy technology platform includes nearer-term commercial opportunities**
- CLBS12 is an ongoing critical limb ischemia study in Japan with SAKIGAKE and ATMP designations for expedited review and eligible for early conditional approval
- CLBS14 protocol design finalized for Phase 3 study in the USA for no option refractory disabling angina
- CLBS16 is an ongoing proof-of-concept Phase 2 study in the USA for coronary microvascular dysfunction and is supported by a grant from the NIH

**Financially stable and debt-free**
- Strong balance sheet (~$33.7 million cash as of June 30, 2019)
- Low operating cash burn (current business plan funded through 2Q 2020)

**Dedicated and highly motivated leadership team with extensive experience in biopharmaceutical development**

<table>
<thead>
<tr>
<th>Ticker Symbol</th>
<th>CLBS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>NASDAQ</td>
</tr>
<tr>
<td>52-Week Price Range</td>
<td>$2.16 - $6.83</td>
</tr>
<tr>
<td>Shares Outstanding (6/30/19)</td>
<td>~10.4 mil</td>
</tr>
<tr>
<td>Cash &amp; Investments (6/30/19)</td>
<td>~$33.7 mil</td>
</tr>
<tr>
<td>Fiscal Year-End</td>
<td>December 31</td>
</tr>
</tbody>
</table>

**POTENTIAL VALUE CREATING MILESTONES**

- **2H 2019** Announce ESCaPE-CMD Phase 2 study topline data
- **2H 2019** Complete enrollment in CLBS12 Phase 2 study
- **1H 2020** Announce CLBS12 Phase 2 study topline data
- **1H 2020** Initiate CLBS14 pivotal Phase 3 study
The potential of Tregs as a therapeutic platform differentiates itself from available therapeutics and almost all other investigational agents in development through:

- Disease modification via restoration of immune tolerance as the most proximal/root cause of the autoimmune disease pathways, in contrast to targeting less pivotal and redundant downstream effects
- Freedom from indiscriminate immune suppression of vital effector functions of the immune system
- Specific homing to disease affected organs, thus targeting tolerance to where it is needed most

More than 700 subjects studied in randomized double-blind placebo-controlled trials provide consistent evidence of therapeutic benefit and tolerance:

- Improved mortality, reduced chest pain and increased exercise tolerance in refractory angina
- Reduced amputation in critical limb ischemia
- Improved function in claudication

CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius’ proprietary platform technology selects and delivers a potent, concentrated population of the patient’s own CD34+ cells for optimal therapeutic benefit.

Simple, rapid, scalable and economical autologous cell therapy process:

- GCSF mobilization eliminates need for surgical bone marrow aspiration
- Four days or less from donation to treatment
- Well characterized, reliable GMP process - easily scaled to meet increasing demand

The potential of Tregs as a therapeutic platform differentiates itself from available therapeutics and almost all other investigational agents in development through:

- Disease modification via restoration of immune tolerance as the most proximal/root cause of the autoimmune disease pathways, in contrast to targeting less pivotal and redundant downstream effects
- Freedom from indiscriminate immune suppression of vital effector functions of the immune system
- Specific homing to disease affected organs, thus targeting tolerance to where it is needed most

3From US study (n=17); Not yet published